<?xml version='1.0' encoding='utf-8'?>
<document id="26807959"><sentence text="How toxic is ibogaine?"><entity charOffset="13-21" id="DDI-PubMed.26807959.s1.e0" text="ibogaine" /></sentence><sentence text="Ibogaine is a psychoactive indole alkaloid found in the African rainforest shrub Tabernanthe Iboga"><entity charOffset="0-8" id="DDI-PubMed.26807959.s2.e0" text="Ibogaine" /></sentence><sentence text=" It is unlicensed but used in the treatment of drug and alcohol addiction"><entity charOffset="56-63" id="DDI-PubMed.26807959.s3.e0" text="alcohol" /></sentence><sentence text=" However, reports of ibogaine's toxicity are cause for concern" /><sentence text="" /><sentence text="To review ibogaine's pharmacokinetics and pharmacodynamics, mechanisms of action and reported toxicity" /><sentence text="" /><sentence text="A search of the literature available on PubMed was done, using the keywords &quot;ibogaine&quot; and &quot;noribogaine&quot;" /><sentence text=" The search criteria were &quot;mechanism of action&quot;, &quot;pharmacokinetics&quot;, &quot;pharmacodynamics&quot;, &quot;neurotransmitters&quot;, &quot;toxicology&quot;, &quot;toxicity&quot;, &quot;cardiac&quot;, &quot;neurotoxic&quot;, &quot;human data&quot;, &quot;animal data&quot;, &quot;addiction&quot;, &quot;anti-addictive&quot;, &quot;withdrawal&quot;, &quot;death&quot; and &quot;fatalities&quot;" /><sentence text=" The searches identified 382 unique references, of which 156 involved human data" /><sentence text=" Further research revealed 14 detailed toxicological case reports" /><sentence text=" PHARMACOKINETICS AND PHARMACODYNAMICS: Ibogaine is metabolized mainly by CYP2D6 to the primary metabolite noribogaine (10-hydroxyibogamine)"><entity charOffset="40-48" id="DDI-PubMed.26807959.s12.e0" text="Ibogaine" /><entity charOffset="107-118" id="DDI-PubMed.26807959.s12.e1" text="noribogaine" /><entity charOffset="120-139" id="DDI-PubMed.26807959.s12.e2" text="10-hydroxyibogamine" /><pair ddi="false" e1="DDI-PubMed.26807959.s12.e0" e2="DDI-PubMed.26807959.s12.e0" /><pair ddi="false" e1="DDI-PubMed.26807959.s12.e0" e2="DDI-PubMed.26807959.s12.e1" /><pair ddi="false" e1="DDI-PubMed.26807959.s12.e0" e2="DDI-PubMed.26807959.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26807959.s12.e1" e2="DDI-PubMed.26807959.s12.e1" /><pair ddi="false" e1="DDI-PubMed.26807959.s12.e1" e2="DDI-PubMed.26807959.s12.e2" /></sentence><sentence text=" Noribogaine is present in clinically relevant concentrations for days, long after ibogaine has been cleared"><entity charOffset="1-12" id="DDI-PubMed.26807959.s13.e0" text="Noribogaine" /><entity charOffset="83-91" id="DDI-PubMed.26807959.s13.e1" text="ibogaine" /><pair ddi="false" e1="DDI-PubMed.26807959.s13.e0" e2="DDI-PubMed.26807959.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26807959.s13.e0" e2="DDI-PubMed.26807959.s13.e1" /></sentence><sentence text="" /><sentence text="Ibogaine and noribogaine interact with multiple neurotransmitter systems"><entity charOffset="0-8" id="DDI-PubMed.26807959.s15.e0" text="Ibogaine" /><entity charOffset="13-24" id="DDI-PubMed.26807959.s15.e1" text="noribogaine" /><pair ddi="false" e1="DDI-PubMed.26807959.s15.e0" e2="DDI-PubMed.26807959.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26807959.s15.e0" e2="DDI-PubMed.26807959.s15.e1" /></sentence><sentence text=" They show micromolar affinity for N-methyl-D-aspartate (NMDA), κ- and μ-opioid receptors and sigma-2 receptor sites"><entity charOffset="35-55" id="DDI-PubMed.26807959.s16.e0" text="N-methyl-D-aspartate" /><entity charOffset="57-61" id="DDI-PubMed.26807959.s16.e1" text="NMDA" /><pair ddi="false" e1="DDI-PubMed.26807959.s16.e0" e2="DDI-PubMed.26807959.s16.e0" /><pair ddi="false" e1="DDI-PubMed.26807959.s16.e0" e2="DDI-PubMed.26807959.s16.e1" /></sentence><sentence text=" Furthermore, ibogaine has been shown to interact with the acetylcholine, serotonin and dopamine systems; it alters the expression of several proteins including substance P, brain-derived neurotrophic factor (BDNF), c-fos and egr-1"><entity charOffset="14-22" id="DDI-PubMed.26807959.s17.e0" text="ibogaine" /><entity charOffset="59-72" id="DDI-PubMed.26807959.s17.e1" text="acetylcholine" /><entity charOffset="74-83" id="DDI-PubMed.26807959.s17.e2" text="serotonin" /><entity charOffset="88-96" id="DDI-PubMed.26807959.s17.e3" text="dopamine" /><pair ddi="false" e1="DDI-PubMed.26807959.s17.e0" e2="DDI-PubMed.26807959.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26807959.s17.e0" e2="DDI-PubMed.26807959.s17.e1" /><pair ddi="false" e1="DDI-PubMed.26807959.s17.e0" e2="DDI-PubMed.26807959.s17.e2" /><pair ddi="false" e1="DDI-PubMed.26807959.s17.e0" e2="DDI-PubMed.26807959.s17.e3" /><pair ddi="false" e1="DDI-PubMed.26807959.s17.e1" e2="DDI-PubMed.26807959.s17.e1" /><pair ddi="false" e1="DDI-PubMed.26807959.s17.e1" e2="DDI-PubMed.26807959.s17.e2" /><pair ddi="false" e1="DDI-PubMed.26807959.s17.e1" e2="DDI-PubMed.26807959.s17.e3" /><pair ddi="false" e1="DDI-PubMed.26807959.s17.e2" e2="DDI-PubMed.26807959.s17.e2" /><pair ddi="false" e1="DDI-PubMed.26807959.s17.e2" e2="DDI-PubMed.26807959.s17.e3" /></sentence><sentence text=" NEUROTOXICITY: Neurodegeneration was shown in rats, probably mediated by stimulation of the inferior olive, which has excitotoxic effects on Purkinje cells in the cerebellum" /><sentence text=" Neurotoxic effects of ibogaine may not be directly relevant to its anti-addictive properties, as no signs of neurotoxicity were found following doses lower than 25 mg/kg intra-peritoneal in rats"><entity charOffset="23-31" id="DDI-PubMed.26807959.s19.e0" text="ibogaine" /></sentence><sentence text=" Noribogaine might be less neurotoxic than ibogaine"><entity charOffset="1-12" id="DDI-PubMed.26807959.s20.e0" text="Noribogaine" /><entity charOffset="43-51" id="DDI-PubMed.26807959.s20.e1" text="ibogaine" /><pair ddi="false" e1="DDI-PubMed.26807959.s20.e0" e2="DDI-PubMed.26807959.s20.e0" /><pair ddi="false" e1="DDI-PubMed.26807959.s20.e0" e2="DDI-PubMed.26807959.s20.e1" /></sentence><sentence text=" CARDIOTOXICITY: Ether-a-go-go-related gene (hERG) potassium channels in the heart might play a crucial role in ibogaine's cardiotoxicity, as hERG channels are vital in the repolarization phase of cardiac action potentials and blockade by ibogaine delays this repolarization, resulting in QT (time interval between the start of the Q wave and the end of the T wave in the electrical cycle of the heart) interval prolongation and, subsequently, in arrhythmias and sudden cardiac arrest"><entity charOffset="51-60" id="DDI-PubMed.26807959.s21.e0" text="potassium" /></sentence><sentence text=" Twenty-seven fatalities have been reported following the ingestion of ibogaine, and pre-existing cardiovascular conditions have been implicated in the death of individuals for which post-mortem data were available"><entity charOffset="71-79" id="DDI-PubMed.26807959.s22.e0" text="ibogaine" /></sentence><sentence text=" However, in this review, 8 case reports are presented which suggest that ibogaine caused ventricular tachyarrhythmias and prolongation of the QT interval in individuals without any pre-existing cardiovascular condition or family history" /><sentence text=" Noribogaine appears at least as harmful to cardiac functioning as ibogaine"><entity charOffset="1-12" id="DDI-PubMed.26807959.s24.e0" text="Noribogaine" /><entity charOffset="67-75" id="DDI-PubMed.26807959.s24.e1" text="ibogaine" /><pair ddi="false" e1="DDI-PubMed.26807959.s24.e0" e2="DDI-PubMed.26807959.s24.e0" /><pair ddi="false" e1="DDI-PubMed.26807959.s24.e0" e2="DDI-PubMed.26807959.s24.e1" /></sentence><sentence text=" TOXICITY FROM DRUG-DRUG INTERACTION: Polymorphism in the CYP2D6 enzyme can influence blood concentrations of both ibogaine and its primary metabolite, which may have implications when a patient is taking other medication that is subject to significant CYP2D6 metabolism"><entity charOffset="115-123" id="DDI-PubMed.26807959.s25.e0" text="ibogaine" /></sentence><sentence text="" /><sentence text="Alternative therapists and drug users are still using iboga extract, root scrapings, and ibogaine hydrochloride to treat drug addiction"><entity charOffset="89-111" id="DDI-PubMed.26807959.s27.e0" text="ibogaine hydrochloride" /></sentence><sentence text=" With limited medical supervision, these are risky experiments and more ibogaine-related deaths are likely to occur, particularly in those with pre-existing cardiac conditions and those taking concurrent medications"><entity charOffset="72-80" id="DDI-PubMed.26807959.s28.e0" text="ibogaine" /></sentence><sentence text="" /></document>